GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Short-Term Capital Lease Obligation

ImmunityBio (FRA:26CA) Short-Term Capital Lease Obligation : €6.34 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Short-Term Capital Lease Obligation?

ImmunityBio's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was €6.34 Mil.

ImmunityBio's quarterly Short-Term Capital Lease Obligation increased from Mar. 2024 (€5.60 Mil) to Jun. 2024 (€5.81 Mil) and increased from Jun. 2024 (€5.81 Mil) to Sep. 2024 (€6.34 Mil).

ImmunityBio's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€2.67 Mil) to Dec. 2022 (€2.50 Mil) but then increased from Dec. 2022 (€2.50 Mil) to Dec. 2023 (€4.81 Mil).

ImmunityBio Short-Term Capital Lease Obligation Historical Data

The historical data trend for ImmunityBio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Short-Term Capital Lease Obligation Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Capital Lease Obligation
- 4.12 2.67 2.50 4.81

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 4.81 5.60 5.81 6.34

ImmunityBio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

ImmunityBio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Short-Term Capital Lease Obligation
Comparable Companies
RVMD NTLA XENE BHVN PRTA CRNX ZLAB IDYA CBAY FTRE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
IBRX:USA 26CA:Germany
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
Website
https://www.immunitybio.com
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

ImmunityBio Headlines

No Headlines